AR076266A1 - Compuestos de azaindol, composiciones farmaceuticas y uso de los compuestos en el tratamiento de hcv - Google Patents
Compuestos de azaindol, composiciones farmaceuticas y uso de los compuestos en el tratamiento de hcvInfo
- Publication number
- AR076266A1 AR076266A1 ARP100101147A ARP100101147A AR076266A1 AR 076266 A1 AR076266 A1 AR 076266A1 AR P100101147 A ARP100101147 A AR P100101147A AR P100101147 A ARP100101147 A AR P100101147A AR 076266 A1 AR076266 A1 AR 076266A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- alkoxy
- heteroaryl
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 31
- 125000003545 alkoxy group Chemical group 0.000 abstract 25
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical group 0.000 abstract 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- -1 nitro, carboxyl Chemical group 0.000 abstract 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos y sus formas y composiciones farmacéuticas de utilidad para tratar una infeccion viral o para afectar la actividad viral al modular la replicacion viral Reivindicacion 1: Un compuesto de la formula (1): o uno de sus ácidos libres, bases libres, sales, hidratos, solvatos, clatratos, isotopologos, racematos, enantiomeros, diastereomeros, estereoisomeros o sus formas polimorficas, en donde W1, W2, W3, W4 están cada uno seleccionados de N o C-R1, en donde N puede estar opcionalmente sustituido con un átomo de O para formar un N-oxido y en donde al menos uno y hasta tres de W1, W2, W3 y W4 son N y el resto son C-R1; X es hidrogeno, halogeno, ciano, nitro, carboxilo, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, formilo, amino, alquil C1-8-amino, amino-carbonilo, hidroxil-carbonilo, alquil C1-8-amino-carbonilo o alquil C1-8-sulfonilo-; Y es arilo, heterociclilo, hetroarilo o heteroaril-1-oxido cada uno sustituido con un sustituyente seleccionado de -N(R2)-SO2-R3, -SO2-N(R4)-R5 o -SO2-R6, -N(H)-R2, -N(R2)-C(O)-N(H)-R4 o -N(R2)-C(O)-R3, en donde arilo, heterociclilo o heteroarilo están cada uno opcionalmente sustituidos con uno o dos sustituyentes adicionales seleccionados, de modo independiente, de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; Z es alquilo C1-8, alquenil C2-8-aIquilo C1-8, alquinil C2-8-alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8-alquilo C1-8, alcoxi C1-8-carbonilo, carboxilo, cicloalquilo C3-14, cicloalquenilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo y heteroarilo está opcionalmente sustituida con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de hidroxi, ciano, nitro, halogeno, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino alquil C1-8-amino, alcoxi C1-8-alquilo C1-8, alquil C1-8-tio, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, alquil C1-8-carboniloxi o amino-sulfonilo; R1 está seleccionado, de modo independiente, de hidrogeno, halogeno, hidroxi, ciano, nitro, alquilo C1-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, alquenilo C2-8, halo-alquenilo C2-8, alcoxi C1-8, halo-alcoxi C1-8, alcoxi C1-8-alquilo C1-8, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, alquil C1-8-carboniloxi, alquil C1-8-carboniloxi-alquilo C1-8, alquil C1-8-carboniloxi-aIcoxi C1-8, amino, alquil C1-8-amino, amino-alquilo C1-8, alquil C1-8-amino-alquilo C1-8, (aril-alquilo C1-8)(alquilo C1-8)amino, amino-alcoxi C1-8, alquil C1-8-amino-alcoxi C1-8, alcoxi C1-8-alquil C1-8-amino-alcoxi C1-8, amino-alquil C1-8-amino-alcoxi C1-8, alquil C1-8-amino-alquil C1-8-amino-alcoxi C1-8, alcoxi C1-8-carbonil-amino, carboxil-amino, amino-carbonilo, amino-carbonil-amino, alquil C1-8-amino-carbonil-amino, alquil C1-8-tio, alquil C1-8-sulfonilo, alquil C1-8-sulfinilo, alquil C1-8-sulfonil-amino, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, cicloalquil C3-14-alcoxi C1-8, cicloalquil C3-14-oxi, arilo, aril-alquilo C1-8, aril-alcoxi C1-8, ariloxi, aril-carbonil-amino, heteroarilo, heteroaril-alquilo C1-8, heteroaril-alcoxi C1-8, heteroariloxi, heterociclilo, heterociclil-alquilo C1-8, heterociclil-alcoxi C1-8, heterocicliloxi o heterociclil-carboniloxi, en donde cada instancia de cicloalquilo C3-14, arilo, heteroarilo y heterociclilo está opcionalmente sustituido con uno, dos, tres o cuatro sustituyentes seleccionados cada uno de halogeno, ciano, alquilo C1-8, alcoxi C1-8, alcoxi C1-8-alquilo C1-8, amino, alquil C1-8-amino, amino-alquilo C1-8 o alquil C1-8-amino-alquilo C1-8; R2 es hidrogeno o alquilo C1-8, opcionalmente sustituido en el alquilo C1-8 con uno o varios sustituyentes seleccionados cada uno de halogeno, hidroxi, ciano, alcoxi C1-8, amino o alquil C1-8-amino; R3 es alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C3-14 está opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; R4 es hidrogeno o alquilo C1-8, opcionalmente sustituido en el alquilo C1-8 con uno o varios sustituyentes seleccionados cada uno de halogeno, hidroxi, ciano o alcoxi C1-8; R5 es hidrogeno, alquilo C1-8, hidroxi-alquilo C1-8, halo-alquilo C1-8, ciano-alquilo C1-8, alcoxi C1-8-alquilo C1-8, amino-alquilo C1-8, alquil C1-8-amino-alquilo C1-8, alquil C1-8-carbonilo, alcoxi C1-8-carbonilo, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo, heteroarilo, heterociclilo y cicloalquilo C3-14 está opcionalmente sustituida con uno o dos sustituyentes seleccionados cada uno de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8, amino o alquil C1-8-amino; y R6 es alquilo C1-8, cicloalquilo C3-14, cicloalquil C3-14-alquilo C1-8, arilo, aril-alquilo C1-8, heteroarilo, heteroaril-alquilo C1-8, heterociclilo o heterociclil-alquilo C1-8, en donde cada instancia de arilo, heteroarilo, cicloalquilo C3-14 y heterociclilo está opcionalmente sustituida con uno o dos sustituyentes seleccionados cada uno de halogeno, alquilo C1-8, halo-alquilo C1-8, alcoxi C1-8, halo-alcoxi C1-8 amino o alquil C1-8-amino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16688309P | 2009-04-06 | 2009-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076266A1 true AR076266A1 (es) | 2011-06-01 |
Family
ID=42124422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101147A AR076266A1 (es) | 2009-04-06 | 2010-04-06 | Compuestos de azaindol, composiciones farmaceuticas y uso de los compuestos en el tratamiento de hcv |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9593108B2 (es) |
| EP (1) | EP2417133A1 (es) |
| AR (1) | AR076266A1 (es) |
| TW (1) | TW201102384A (es) |
| WO (1) | WO2010117935A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010117936A1 (en) * | 2009-04-06 | 2010-10-14 | Schering Corporation | Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
| BR112014000314A2 (pt) | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de pirrolo pirimidina |
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US9233961B2 (en) * | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| CN105130987B (zh) * | 2015-10-08 | 2016-09-28 | 吉林百年汉克制药有限公司 | 一种医药中间体吡咯并吡啶类化合物的合成方法 |
| RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
| ES2974634T3 (es) | 2018-12-21 | 2024-06-28 | Celgene Corp | Inhibidores de tienopiridinas de RIPK2 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| WO2022093552A2 (en) * | 2020-10-16 | 2022-05-05 | Saint Louis Univeristy | Rev-erb agonists |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| EP0923579A1 (en) | 1996-08-27 | 1999-06-23 | Novartis AG | Herbicidal s-substituted 1,2,4,6-thiatriazines |
| DE19915178A1 (de) | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
| EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| TW200306191A (en) * | 2002-02-22 | 2003-11-16 | Teijin Ltd | Pyrrolopyrimidine derivatives |
| GB0307891D0 (en) * | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| RU2382786C2 (ru) | 2004-12-24 | 2010-02-27 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Бициклические производные пиррола |
| JPWO2006112331A1 (ja) | 2005-04-13 | 2008-12-11 | 大日本住友製薬株式会社 | 新規縮合ピロール誘導体 |
| EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| BRPI0620643A2 (pt) | 2005-12-23 | 2011-12-20 | Novartis Ag | compostos de heterocìclicos condensados úteis como inibidores de dpp-iv, formulações farmacêuticas, produtos e usos dos compostos |
| GB0708141D0 (en) * | 2007-04-26 | 2007-06-06 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| WO2010117936A1 (en) * | 2009-04-06 | 2010-10-14 | Schering Corporation | Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
-
2010
- 2010-04-05 WO PCT/US2010/029928 patent/WO2010117935A1/en not_active Ceased
- 2010-04-05 EP EP10713288A patent/EP2417133A1/en not_active Withdrawn
- 2010-04-05 US US13/259,283 patent/US9593108B2/en not_active Expired - Fee Related
- 2010-04-06 TW TW099110595A patent/TW201102384A/zh unknown
- 2010-04-06 AR ARP100101147A patent/AR076266A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20120135999A1 (en) | 2012-05-31 |
| US9593108B2 (en) | 2017-03-14 |
| WO2010117935A1 (en) | 2010-10-14 |
| EP2417133A1 (en) | 2012-02-15 |
| TW201102384A (en) | 2011-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076266A1 (es) | Compuestos de azaindol, composiciones farmaceuticas y uso de los compuestos en el tratamiento de hcv | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| AR076267A1 (es) | Combinaciones de inhibidor de vhc y agentes terapeuticos. metodo. uso. | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR040335A1 (es) | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| AR070127A1 (es) | Pirrolo - pirimidinas y pirrolo -piridinas | |
| CU20160181A7 (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| AR065927A1 (es) | Derivados de 5,6-dihidro-1h-piridin-2-ona | |
| ECSP12011867A (es) | Derivados bencimidazol-imidazol | |
| AR043682A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los contienen y su uso para el tratamiento del crecimiento celular anormal | |
| AR062110A1 (es) | Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico | |
| AR071739A1 (es) | Inhibidores de transcriptasa reversa | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR050181A1 (es) | Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR044342A1 (es) | Derivados de bencimidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |